Replimune Group, Inc.
Replimune Group, Inc. (NASDAQ: REPL) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies designed to transform cancer treatment by maximizing immune system activation against tumors. The company's proprietary RPx platform is based on an engineered strain of herpes simplex virus 1… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Replimune Group, Inc. does
In the company’s own words
Replimune Group, Inc. (NASDAQ: REPL) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies designed to transform cancer treatment by maximizing immune system activation against tumors. The company's proprietary RPx platform is based on an engineered strain of herpes simplex virus 1 with multiple therapeutic payloads intended to achieve dual local and systemic anti-tumor activity through direct virus-mediated tumor cell killing and the induction of durable systemic immune responses.
The company's lead product candidate, RP1 (vusolimogene oderparepvec), is a selectively replicating HSV-1 virus expressing GALV-GP R(-) and human GM-CSF. RP1 has been evaluated in the IGNYTE clinical trial for advanced melanoma, demonstrating a confirmed overall response rate of 32.9 percent when combined with nivolumab in anti-PD-1 failed patients, with a median overall survival of 32.9 months and three-year survival rates of 47.8 percent across all treated patients. The company submitted a Biologics License Application to the FDA in November 2024 under the accelerated approval pathway and received Breakthrough Therapy designation. Following two Complete Response Letters, the company resubmitted the BLA in 2025 with an FDA action date of August 2, 2026.
Pipeline candidates include RP2 (sturlimgene erparepvec), engineered to express an anti-CTLA-4 antibody-like molecule for enhanced immune activation, currently in development for metastatic uveal melanoma through the REVEAL Phase 2/3 trial. RP3, designed with additional immune co-stimulatory pathways, is not currently being pursued due to program prioritization.
Replimune operates a dedicated in-house manufacturing facility in Framingham, Massachusetts, spanning approximately 63,000 square feet and designed to support full global commercialization. The company collaborates with Bristol Myers Squibb, which provides nivolumab at no cost for clinical trials, and maintains a signal-finding collaboration with Roche for hepatocellular carcinoma studies. The company's approach combines multiple mechanisms of action into off-the-shelf therapies intended to work synergistically with checkpoint inhibitor therapies and other cancer treatments.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- WOBURN, MA
- Fiscal year end
- March
- CIK
- 1737953
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Replimune Group, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Replimune Group, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Replimune Group, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Replimune Group, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Replimune Group, Inc.'s last four quarterly filings that the numbers alone won't show?”